ClinicalTrials.gg
RecruitingNCT04010422Updated Apr 18, 2023

Ocular Function in Autism Spectrum Disorder

An observational study in Autism and Ocular Surface Disease, sponsored by National Taiwan University Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 20 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-18.

Sponsored by National Taiwan University Hospital · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2023, 2 years 10 months ago, but the record still lists the study as recruiting.
  • Started May 2019; still recruiting 7 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
100
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Autistic Disorder by National Taiwan University Hospital — 6 open to participants now, 6 under way, none of them phase 3. Autistic Disorder · National Taiwan University Hospital.

Started
2019
the only one that year
Observational
6 of 12
3 open now
Registered
4th of 12
by date

Among the 12 studies in Autistic Disorder by National Taiwan University Hospital, this one is the only one that started in 2019, is one of 6 observational ones, and was the 4th registered.

Autistic Disorder

1,035 studies on the registry are indexed under Autistic Disorder; 270 are open to participants now.

Browse Autistic Disorder studies →

Open to participants now

6 of the 12 studies in Autistic Disorder by National Taiwan University Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 184 Autistic Disorder studies recruiting now, 33 (18%) set no upper age limit and 144 (78%) stop at 75 or younger; 150 take children under 18; 56 take healthy volunteers.

This study: 20 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Autistic Disorder by National Taiwan University Hospital, or all of them as a file.
02

Study summary

This study will investigate the visual function in individuals with ASD, with a particular focus on the ocular surface condition and visual function assessment.

Read the detailed description

Anomalies in visual information processing can have a major effect on the life quality of individuals with autism spectrum disorders (ASD), including eye gaze abnormality, higher frequency of refractive errors (e.g., astigmatism, hypermetropia, and anisometropia), strabismus, abnormal blinking rate, disturbed eye movements that may be associated with or aggravated social communication deficits of ASD. However, little is known about the ocular surface conditions. This study will investigate the visual function in individuals with ASD, with a particular focus on the ocular surface condition. We plan to recruit 50 adults with ASD and 50 age-/sex-matched typically developing controls in this project, and perform visual function assessment.

03

Conditions studied

  • Autism
  • Ocular Surface Disease

Browse trials for

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

This is an observation study. We will recruit 50 adults with autism spectrum disorder aging over 20 years old from the Psychiatry Department, National Taiwan University Hospital. We will also recruit 50 adults without autism spectrum disorder aging over 20 years old from the Ophthalmology Department, National Taiwan University Hospital.

Eligibility criteria

ASD group:

Inclusion Criteria:

  1. Having a clinical diagnosis of autism spectrum disorder
  2. Aged over 20 years; able to read and sign an form.
  3. Clear conscious and can follow the instruction of opening eyes and movement toward all direction.

Exclusion Criteria:

  1. Unable to cooperate with the examinations.
  2. Younger than 20 years old.

TD group:

Inclusion Criteria:

  1. Aged over 20 years; able to read and sign an informed consent form.
  2. Clear conscious and can follow the instruction of opening eyes and movement toward all direction.

Exclusion Criteria:

  1. Unable to cooperate with the examinations.
  2. Younger than 20 years old.
  3. Having a clinical diagnosis of autism spectrum disorder
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • ASD group

    Inclusion Criteria: 1. Having a clinical diagnosis of autism spectrum disorder 2. Aged over 20 years; able to read and sign an informed consent form. 3. Clear conscious and can follow the instruction of opening eyes and movement toward all direction. Exclusion Criteria: 1. Unable to cooperate with the examinations. 2. Younger than 20 years old

    Diagnostic Test: no intervention

  • TD Group

    Inclusion Criteria: 1. Aged over 20 years; able to read and sign an informed consent form. 2. Clear conscious and can follow the instruction of opening eyes and movement toward all direction. Exclusion Criteria: 1. Unable to cooperate with the examinations. 2. Younger than 20 years old. 3. Having a clinical diagnosis of autism spectrum disorder

    Diagnostic Test: no intervention

Interventions

  • Diagnostic testno intervention

    no intervention

06

What researchers measure

Primary outcomes

  1. cornea innervation

    The participants will undergo HRT in vivo confocal microscopy. It is a laser scanning confocal microscope, operating by scanning a 670 nm laser beam in a raster pattern over the field of view. The system uses a high numerical aperture 63x objective lens (0.9 NA), and produces images with high contrast and better axial resolution (7.6 µm) than other in vivo confocal systems (9 µm for the TSCM and 24 µm for the Confoscan). The HRT-RCM provides new built-in software for 3D imaging of the corneal structure. Quantitative imaging of the subbasal nerve plexus could be per-formed by CCMetrics system, a custom software program developed at the University of Manchester.

    Time frame: 30 min

  2. Blinking reflex

    Blinking rates manually calculated by two different research personnel and Tobii Pro X3-120 under two conditions: viewing preset film on the laptop and casual conversation with interviewer.

    Time frame: 30 min

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2019 (actual). Primary completion is estimated for Dec 2023, 55 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2019
First posted
Jul 8, 2019
StartActual
May 15, 2019
Primary completionEst.
Dec 31, 2023
CompletionEst.
Dec 31, 2023
Last update
Apr 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04010422
Responsible party
Sponsor
First posted
Jul 8, 2019
Start date
May 15, 2019
Primary completion
Dec 31, 2023 (estimated)
Completion
Dec 31, 2023 (estimated)
Last update
Apr 18, 2023

Study contacts

Yi Ling Chien
Contact
ylchien@hotmail.com
886-2-2312-3456 ext. 66013
Yi Ling Chien
principal investigator · National Taiwan University Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion